For several months now, Indian generic companies have been actively seeking approvals for phase III clinical trials, bio-equivalence studies, etc, from CDSCO to be ready with market approvals to launch low-cost, generic versions of Semaglutide as soon as Novo Nordisks patent rights on the medicine get over
These cancers can cause systemic symptoms, including night sweats, unexplained weight loss, and persistent fatigue
And dose adjustments are based on genuine biological response rather than storage artifacts
It may be substituted at the pharmacy without the intervention of the healthcare provider, subject to state laws, similar to how generic drugs are substituted, Stein says
Another possible reason may be a direct effect of tirzepatide on the retina, since the GLP-1 receptor is expressed in the retina [9]